CHEK2 1100delC in Breast and Colorectal Cancer Patients
Author Information
Author(s): Anna Isinger, Misha Bhat, Ake Borg, Mef Nilbert
Primary Institution: Lund University
Hypothesis
Is the CHEK2 1100delC mutation a significant contributor to double primary breast and colorectal cancer?
Conclusion
The CHEK2 1100delC mutation is not a major cause of double primary breast and colorectal cancer in Sweden.
Supporting Evidence
- 2.5% of the patients carried the CHEK2 1100delC mutation.
- The mutation frequency in the control group was 1%.
- The study analyzed 75 patients with metachronous tumors.
Takeaway
This study looked at women with both breast and colorectal cancer to see if a specific gene mutation was causing their cancers, but it turns out that it probably isn't.
Methodology
The study used a population-based cancer registry to identify patients and sequenced tumor material to assess the CHEK2 1100delC mutation.
Limitations
The small sample size limits the strength of the findings.
Participant Demographics
Women diagnosed with both breast and colorectal cancer.
Statistical Information
P-Value
0.26
Statistical Significance
p = 0.26
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website